Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Private Capital To Enter High-End Health Care Market

This article was originally published in PharmAsia News

Executive Summary

San Paulo Mans Hospital, the first patient membership hospital in Beijing, has commenced operation, marking the beginning of private capital flowing into China's high-end health care market. Most analysts hold optimistic views about the development and point out that private investment in luxury health care will meet the requirements of a growing high-income market. As the government puts priority on supporting basic health care and providing insurance to its disadvantaged population, the latest involvement by the private sector frees it to focus on formulating regulations and standards, setting admittance thresholds, enhancing market supervision, providing reasonable subsidies and creating a fair competition environment for private capital. (Click here for more - Chinese Language)

You may also be interested in...



Ahead Of Ryoncil’s Advisory Committee, Citizen Petition Opposes Approval For Pediatric GVHD

Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.

Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH

Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.

Like Consumer Health Ad Claims About COVID-19, Customer Testimonials Are False And Misleading

Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading. 

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel